Kymera Therapeutics is a clinical-stage biotechnology company advancing the field of targeted protein degradation (TPD) to create transformative medicines for serious health conditions. The company develops oral small molecule degraders aimed at treating immunological diseases and oncology targets that traditional therapeutics struggle to address. Founded in 2016, Kymera has made significant strides in bringing innovative therapies to clinical development, focusing on improving patient outcomes through rigorous scientific exploration. The company fosters a collaborative and inclusive culture that values trust, transparency, and diversity, recognizing that such an environment enhances creativity and drives successful outcomes. At Kymera, employees are inspired to pioneer meaningful solutions and are encouraged to contribute to a mission that has the potential to dramatically improve lives.